Care Delayed is Care Denied: Benefits Beyond Glycaemic Control with a Single Pill Combination of Empagliflozin and Linagliptin

01 Jul 2022
Care Delayed is Care Denied: Benefits Beyond
Glycaemic Control with a Single Pill Combination
of Empagliflozin and Linaglip
3.9 million Malaysians have diabetes, representing a staggering 1in 5 adults. We also have the highest rate of diabetes in Asia and to compound matters, more than half of them will develop chronic kidney disease (CKD) during their lifetime. The incidence of CKD is also rising relentlessly year after year, evolving rapidly into not only a Malaysian, but a global non-communicable disease pandemic. Progressive CKD may not only lead to end-stage renal disease but markedly increases mortality risks, where this grows more than ten times fold if one happens to have CKD.

Related MIMS Drugs

Editor's Recommendations